[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Helsinki\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":460},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,50,86,109,135,177,214,245,277,305,331,356,384,405,440],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100638045","impact-of-dietary-fibre-supplementation-on-gut-symptoms-in-healthy-participants-100638045",false,"NCT07587424","Impact of Dietary Fibre Supplementation on Gut Symptoms in Healthy Participants","The Effect of Dietary Fibre Supplementation on Gastrointestinal Symptoms in Healthy Participants - KiVa-trial","KiVa","Inclusion Criteria:\n\n* healthy male and female\n* aged 18-65 years\n* experience gastrointestinal discomfort during or after eating\n* willing to commit to the 6-week study period and follow the study schedule.\n\nExclusion Criteria:\n\n* Body mass index ≤ 18.5 or ≥ 35 kg\u002Fm².\n* Inflammatory bowel diseases, irritable bowel syndrome (IBS), celiac disease, endocrine or lipid metabolism disorders, liver or kidney diseases, cancer within the past 5 years, eating disorders.\n* Medication for gastrointestinal symptoms, bowel function, diabetes, or hypercholesterolemia.\n* Regular or recent use of antibiotics (within the last 3 months).\n* Food allergies to the ingredients of the study products.\n* Heavy, long-duration exercise several times a week.\n* Smoking, use of snus or nicotine pouches.\n* Planned or ongoing pregnancy or breastfeeding.\n* In addition, the site-specific principal investigator may exclude a person due to any illness, medication, or factor they deem relevant for the participant's health and safety or for the conduct of the study.",true,"ALL","18 Years","65 Years",{"count":22,"type":23},28,"ESTIMATED","INTERVENTIONAL",[26],"NA","Fibres found in food are mainly carbohydrates that are not broken down or absorbed during human digestion but instead pass to the colon to be fermented by microbes. Gases produced during bacterial fermentation (hydrogen, methane, and carbon dioxide), can cause unpleasant gastrointestinal symptoms in some individuals, such as bloating, flatulence, and stomach pain. Gas production varies between individuals and is influenced by the chemical structure of dietary fibres, the gut microbes' ability to ferment fibre, intestinal pH, and the transit time of intestinal contents. This randomized clinical trial in healthy adults will investigate how individual variations in the microbiome influence the level of gastrointestinal (GI) symptoms induced by different fibre types during short-term exposure.",[29],"Gastrointestinal Symptoms",[31,32,33,34,35,36],"dietary fibre","dietary fiber","gut symptoms","microbiota","microbiome","gastrointestinal discomfort","NOT_YET_RECRUITING","2026-05-07",{"date":40,"type":41},"2026-05-14","ACTUAL",{"date":43,"type":23},"2026-08-17",{"date":45,"type":23},"2026-09-30",{"name":47,"class":48},"University of Helsinki","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":49},"100607480","saga-for-toddlers-supporting-childrens-linguistic-and-socio-emotional-development-in-early-childhood-education-and-care-100607480","NCT07189104","SAGA for Toddlers. Supporting Children's Linguistic and Socio-Emotional Development in Early Childhood Education and Care","SAGA-T","Inclusion Criteria:\n\n* 11 to 36 -months old at the start of the study\n* Living in Finland\n* Attending Swedish speaking early childhood education and care\n\nExclusion Criteria:\n\n* None","11 Months","36 Months",{"count":60,"type":23},120,[26],"The goal of this study is to investigate whether a shared reading intervention including emotion and mind-related dialogues (SAGA for Toddlers) supports the development of 11 to 36 moth-old-children in early childhood education and care.\n\nThe main questions it aims to answer are:\n\n1. Does the SAGA model support children's social-emotional development?\n2. Does the SAGA model support children's language development?\n\nThe participating children will attend the intervention at the early childhood education and care.\n\nThe participating personnel at the early childhood education and care will receive training, implement the intervention, and answer questionnaires.\n\nThe participating caregivers will attend caregiver-evenings and answers questionnaires.",[64,65],"Social Emotional Competence","Language Development",[67,68,69,70,71,72,73,74,75,76],"social-emotional development","language development","intervention","toddlers","early childhood education and care","caregivers","mentalization theory","SAGA model","group intervention","shared reading intervention","RECRUITING","2026-05-04",{"date":80,"type":41},"2026-05-08",{"date":82,"type":41},"2025-09-25",{"date":84,"type":23},"2027-04",{"name":47,"class":48},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":49},"100636547","stability-of-orthodontic-treatment-of-anterior-open-bite-100636547","NCT07567105","Stability of Orthodontic Treatment of Anterior Open-bite","Orthodontic Correction of Anterior Open-bite, Treatment Outcome Stability and Impact of Anterior Open Bite Malocclusion","Inclusion Criteria:\n\n\\- Clinical diagnosis of anterior open bite malocclusion, past or present\n\nExclusion Criteria:\n\n* No malocclusion\n* craniofacial genetic anomaly",{"count":94,"type":23},80,"OBSERVATIONAL","The study aims to explore how an open bite malocclusion affects daily life of an individual, is its orthodontic treatment effective, and what kind of burden of care the treatment has caused.",[98],"Open Bite",[100],"Anterior open bite","2026-04-27",{"date":103,"type":41},"2026-05-05",{"date":105,"type":41},"2025-12-01",{"date":107,"type":23},"2030-07-30",{"name":47,"class":48},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":49},"100501997","the-prognostic-impact-of-symptoms-and-lesion-depth-in-partial-removal-of-carious-tissue-100501997","NCT05816525","The Prognostic Impact of Symptoms and Lesion Depth in Partial Removal of Carious Tissue","Inclusion Criteria:\n\n* the patient is communicating in the Finnish or English language\n* a deep primary or secondary carious lesion in 1st or 2nd premolar or molar on occlusal or proximal surface, extending to the deepest quarter of dentine assessed from the radiograph\n* asymptomatic or symptoms not more severe than reversible pulpitis (mild pulpitis according to the new pulpitis classification proposal)\n* pulp responding to the electric pulp testing and cold testing\n* the periodontal stage of the tooth should be I or II.\n\nIn case the patient has several teeth fulfilling the inclusion criteria, the one with the deepest lesion and\u002For most severe symptoms is chosen to the study.\n\nExclusion Criteria:\n\n* general medical condition which makes the patient more susceptible to odontogenic infection complications\n* pregnancy, breastfeeding\n* mental retardation, memory disorder\n* the carious lesion is extending to more than three surfaces or to both proximal surfaces\n* the tooth has previous other filling(s): i) extending deeper than to the outer third of dentine; or ii) the filling is larger than Class I or II; or iii) Class II filling is not restricted to enamel; or iv) the filling has secondary\u002Fresidual caries\n* the tooth is not restorable\n* periapical changes in the periapical radiograph\n* sensitivity to percussion; swelling; sinus tract; increased mobility; resorption\n* furcal lesion more severe than Class I\n* ongoing orthodontic treatment\n* declining to sign the written consent.","50 Years",{"count":117,"type":23},100,"The goal of this prospective, observational clinical cohort study is to study the effect of the preoperative condition of the tooth on the outcome of partial removal of carious tissue in mature teeth in adults. The main questions the study aims to answer are:\n\n* Do preoperative symptoms affect the outcome?\n* Does the depth of the carious lesion affect the outcome?\n\nOne hundred participants will be recruited. Patients who meet the eligibility criteria will be asked to give their informed consent to participate in the study. Partial carious tissue removal will be performed regardless of participation in the study because selective carious tissue removal is the standard treatment of choice for a vital tooth with a deep carious lesion according to the Finnish national treatment guidelines. Participants will be asked to fill in a questionnaire regarding symptoms 7 days post-treatment. The teeth will then be followed up for 12-24 months.\n\nThe null hypothesis is that there is no difference in the success between i) deep and extremely deep carious lesions and ii) initial and mild pulpitis.",[120,121,122],"Deep Caries","Pulpitis Reversible","Pulp Hyperemia",[124,125,126],"vital pulp therapy","deep carious lesion","selective carious tissue removal","2026-04-17",{"date":129,"type":41},"2026-04-22",{"date":131,"type":41},"2023-04-21",{"date":133,"type":23},"2027-12-31",{"name":47,"class":48},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":115,"enrollmentInfo":142,"targetDuration":4,"studyType":24,"phases":143,"briefSummary":144,"conditions":145,"keywords":161,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},"100609268","infant-microbiota-restoration-with-maternal-microbes-100609268","NCT07212361","Infant Microbiota Restoration With Maternal Microbes","MaMi","Inclusion Criteria:\n\n* Healthy mother and healthy pregnancy\n* Singleton pregnancy,\n* Mothers who speak Finnish or Swedish\n* Mothers who are planning to breastfeed or give breastmilk by bottle to the infant\n* Infants who are expected to be healthy and who will not require BCG vaccination.\n\nExclusion Criteria:\n\n* Participants who lives further than a 2-hour drive from Meilahti, Helsinki, Finland\n* Mothers who are not planning to breastfeed or feed breastmilk by bottle to the infant\n* Mothers who are diagnosed with gestational diabetes, pre-eclampsia or who have been receiving antibiotics during the pregnancy or delivery\n* Premature infants born before the pregnancy week 37\n* Infants, who are born by urgent cesarean section or emergency cesarean section\n* Infants, who receive antibiotics during the first week of life\n* Infants, who are diagnosed with a disease, congenital anomaly or who receive less than 9 Apgar points at 5 minutes.\n* Infants, who receive BCG-vaccine",{"count":117,"type":23},[26],"The goal of this clinical trial is to test the ability of different bacterial products in restoring natural gut microbiota in C-section born infants. The main question it aims to answer is:\n\nDo maternally derived strains of bacteria perform better than commercially available probiotic strains in restoring the gut microbiota of C-section born infants? Researchers will compare the gut microbiota of treated infants to that of untreated C-section born infants and untreated vaginally born infants to see if the bacterial treatments cause the microbiota to resemble that of vaginally born infants.\n\nParticipants will be given a bacterial product orally once daily for either one or four weeks and be asked to collect faecal, urine and saliva samples.",[146,147,148,149,150,151,152,153,154,155,156,157,158,159,160],"Infant, Newborn","Gut -Microbiota","Gut Dysbiosis","Cesarean Delivery Affecting Newborn","Cesarean Section","Vaginal Delivery","Gastrointestinal Microbiota","Microbiota, Cesarean Section, Probiotics, Dysbiosis","Feces","Delivery, Obstetric","Microbiota","Microbiology","Humans","Pregnancy","Neonate",[162,163,164,165,166,167],"Infant","newborn","cesarean section","neonate","restore","gut microbiota","2025-09-30",{"date":170,"type":41},"2025-10-08",{"date":172,"type":41},"2025-07-17",{"date":174,"type":23},"2035-12-31",{"name":47,"class":48},2,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":17,"sex":18,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":24,"phases":186,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":49},"100604679","physiological-hormonal-and-dna-based-mechanisms-of-psychosocial-stress-and-therapeutic-effect-100604679","NCT07152652","Physiological, Hormonal, and DNA-based Mechanisms of Psychosocial Stress and Therapeutic Effect","Inclusion Criteria:\n\n* Adult (age 18 and above)\n* Student in the University of Helsinki, Finland\n* Able to speak\u002Fread Finnish, Swedish, or English\n\nExclusion Criteria:\n\n* None","18 Months",{"count":185,"type":23},148,[26],"The goal of this trial is to learn if the Groups 4 Health (G4H) intervention is effective in supporting student well-being at the University of Helsinki. It will also learn about the factors that may influence the efficacy of the intervention (such as facilitators characteristics, stress physiology and changes in gene expression). The main questions it aims to answer are:\n\n1. Is the G4H intervention effective and cost-effective in supporting student well-being?\n2. To what extent participants' physiological, hormonal, or molecular characteristics mediate the therapeutic effect of the G4H\n3. To what extent participants' genotype moderates the effect of the G4H\n4. To what extent facilitators' characteristics mediate or moderate the effect of the G4H\n\nData is collected from both the intervention participants and the facilitators.\n\nThe G4H facilitators will:\n\n* Facilitate the G4H intervention.\n* Fill in questionnaires and provide physiological and molecular measurements before, during, and after the G4H intervention.\n\nThe G4H participants will:\n\n* Participate in the G4H intervention.\n* Fill in questionnaires and provide physiological, hormonal and molecular measurements before, during, and after the G4H intervention.",[189,190],"Well-Being, Psychological","Loneliness",[192,193,194,190,195,196,197,198,199,200,201,202,203,204,205],"University Students","Group Intervention","Mental Health","Social Isolation","Anxiety","Depression","Social Anxiety","Social Cohesion","Groups 4 Health","Stress system functioning","Genetics","Epigenetics","Experience Sampling Method","Stress physiology","2025-09-23",{"date":208,"type":41},"2025-09-29",{"date":210,"type":41},"2025-09-12",{"date":212,"type":23},"2028-12",{"name":47,"class":48},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":222,"minAge":19,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":24,"phases":225,"briefSummary":226,"conditions":227,"keywords":230,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":49},"100601594","tdcs-intervention-in-breast-cancer-survivors-with-and-without-obesity-reporting-cognitive-impairment-100601594","NCT07112521","tDCS Intervention in Breast Cancer Survivors With and Without Obesity Reporting Cognitive Impairment","Evaluating the Efficacy of Home-Based tDCS for Cancer-Related Cognitive Impairment and Its Moderation by Obesity: A Double-Blind Randomized Controlled Trial.","LUMINA-brain","Inclusion Criteria:\n\n* Female\n* Over 18 years old\n* Diagnosed with primary adult-onset breast cancer within the last 5 years\n* Completed all active cancer treatments at least 3 months prior to study participation\n* Capable of fulfilling study requirements, including having internet access.\n* Fluent in either Finnish or English\n* Have normal or corrected vision and hearing\n* Right-handed (based on the Edinburgh Handedness Inventory score; Oldfield, 1971)\n\nExclusion Criteria:\n\n* Have received primary cancer treatment (chemotherapy, radiotherapy, immunotherapy, or surgery) within the last 3 months\n* Have a history of childhood-onset cancer\n* Present with acute eczema on the scalp\n* Diagnosed with dementia, Alzheimer's disease, multiple sclerosis, or - Parkinson's disease\n* Have experienced unconsciousness for more than five minutes due to a head\u002Fbrain injury within the last 10 years\n* Have a history of stroke or transient ischemic attack\n* Suffer from claustrophobia\n* Are pregnant or breastfeeding\n* Have any of the following medical implants or devices: cardiac implantable electronic devices, metallic intraocular foreign bodies, neurostimulation systems, cochlear\u002Fear implants, drug infusion pumps, catheters with metal components, metallic fragments (e.g., bullets), cerebral aneurysm clips, magnetic dental implants, tissue expanders, artificial limbs, non-removable piercings, or face tattoos.\n* Weight exceeding 250 kg (the MRI table weight limit) or they are unable to fit within the 70 cm diameter bore of the MRI machine","FEMALE",{"count":224,"type":23},40,[26],"The goal of this intervention is to investigate whether transcranial Direct Current Stimulation (tDCS) can alleviate Cancer-Related Cognitive Impairment (CRCI) in breast cancer survivors, as measured by changes in brain structures and cognitive performance. To assess the efficacy of tDCS, the investigators will compare outcomes between participants receiving active stimulation and those receiving sham stimulation (a placebo condition where participants believe they are receiving stimulation, but are not).\n\nParticipants will:\n\n* Undergo a baseline MRI session\n* Receive either active or sham tDCS for six weeks\n* Undergo a follow-up MRI session\n* Complete cognitive tests and respond to psychosocial questionnaires before, during, and after the tDCS intervention",[228,229],"Breast Cancer Survivor","Obesity, Overweight",[231,232,233,234,235,236],"tdcs","CRCI","breast cancer survivors","obesity","transcranial direct current stimulation","cancer related cognitive impairment","2025-08-29",{"date":239,"type":41},"2025-09-02",{"date":241,"type":23},"2025-09-01",{"date":243,"type":23},"2027-01",{"name":47,"class":48},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":17,"sex":18,"minAge":251,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":24,"phases":254,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":49},"100479229","efficacy-of-music-therapy-and-digital-music-rehabilitation-in-dementia-100479229","NCT05520268","Efficacy of Music Therapy and Digital Music Rehabilitation in Dementia","Inclusion Criteria:\n\n* Diagnosed dementia (according to International Classification of Diseases \\[ICD\\] criteria), which is mild \\[Clinical Dementia Rating (CDR) score: 0.5-1, Global Deterioration Scale (GDS) score: 3-4\\], moderate (CDR: 2, GDS: 4-6), or severe (CDR: 3, GDS: 6-7) dementia\n* Age ≥ 60 years\n* Finnish-speaking (or bilingual; the study is performed in Finnish)\n* Stable physical and somatic condition (no major changes in psychotropic medication during the last 3 months)\n* Physically and cognitively able to take part in the intervention and assessments.\n\nExclusion Criteria:\n\n* Prior severe psychiatric illness or substance abuse\n* Major hearing or visual impairment","60 Years",{"count":253,"type":23},192,[26],"This study evaluates the applicability and clinical efficacy of conventional music therapy and digital music rehabilitation for dementia in home and care home settings.",[257],"Dementia",[259,260,261,262,263,264,265,266,267,268],"music therapy","music-based rehabilitation","digital intervention","cognitive functioning","memory","emotion","mood","quality of life","electroencephalography","magnetic resonance imaging","2025-02-03",{"date":271,"type":41},"2025-02-06",{"date":273,"type":41},"2022-09-01",{"date":275,"type":23},"2025-12-31",{"name":47,"class":48},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":49},"100577568","nutfinforce-the-impact-of-digitally-delivered-lifestyle-performance-medicine-intervention-on-defense-performance-in-finland-100577568","NCT06799988","NutFinForce: The Impact of Digitally Delivered Lifestyle Performance Medicine Intervention on Defense Performance in Finland","NUTFINFORCE: THE IMPACT OF DIGITALLY DELIVERED LIFESTYLE PERFORMANCE MEDICINE INTERVENTION ON DEFENSE PERFORMANCE IN FINLAND","NutFinForce","Inclusion Criteria:\n\n* The participants for the intervention are recruited along with the invitation process of the Finnish Defense Forces in such a way that it does not interfere with the actual goal itself: attending the military service.\n\nAttendance for the intervention, suspension of the intervention or not attending is not known by the Defense Forces and does not influence terms of service\n\nExclusion Criteria:\n\n* Not attending the military service","30 Years",{"count":287,"type":23},5000,"Summaries are in Finnish for attendees are availabe and reviewed in ethical approcval process",[290],"No Condition",[292,293,294,295,296],"Nutrition","Eating habits","Digital","Behavior change","Performance medicine","2025-01-23",{"date":299,"type":41},"2025-01-29",{"date":301,"type":23},"2025-03-15",{"date":303,"type":23},"2029-12-31",{"name":47,"class":48},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":49},"100551819","hfpef-project-heart-failure-phenotyping---exploring-the-fingerprints-100551819","NCT06465043","HFPEF-project: Heart Failure Phenotyping - Exploring the Fingerprints","HFPEF-project: Heart Failure Phenotyping - Exploring the Fingerprints Prospective Observational Study Aiming At Detailed Characterization and Deep Phenotyping of Patients with Heart Failure and Preserved Ejection Fraction (LVEF>40%)","Inclusion Criteria:\n\n* Hospitalisation for heart failure or debilitating dyspnoea (NYHA II-IV) and a diagnosis of HFpEF.\n* Left ventricular ejection fraction (LVEF) \\>40% in the preceding 12 months or during a period of hospitalisation as determined by either cardiac ultrasound, MRI, left ventricular echocardiography, or isotope imaging.\n* NTproBNP \\> 300 pg\u002Fml (or BNP \\> 100 pg\u002Fml) during hospitalisation or NTproBNP \\> 125 pg\u002Fml in outpatients.\n* Impaired myocardial relaxation (diastolic dysfunction) as determined by tissue doppler imaging (TDI: lateral mitral annulus velocity, lat E\\' \\<9cm\u002Fs or septal annulus velocity, sept E\\' \\<8 cm\u002Fs)\n* Both previously undiagnosed, de-novo heart failure patients and patients admitted to hospital for acute exacerbation of known heart failure will be included in the study.\n\nExclusion Criteria:\n\n* Age \\>85 years\n* Significant aortic valve stenosis (AVA ≤1.0 cm2)\n* Primary (structural) mitral valve disease with grade III-IV insufficiency or significant stenosis (MVA\\<1.5 cm2)\n* Other severe valvular defect (e.g. secondary severe mitral or severe tricuspid insufficiency)\n* Previous LVEF \\< 40% (HFrEF or HF with improved EF)\n* Recent acute coronary syndrome (\\< 3 months) or myocardial infarction with ST elevations (STEMI) within 12 months\n* Previous open heart surgery (CABG\u002Fvalvular) or percutaneous valvular interventio\n* Previously known specific myocardial disease (hypertrophic cardiomyopathy, non-compaction cardiomyopathy (LVNC), right ventricular arrhythmogenic cardiomyopathy (ARVC), cardiac amyloidosis, cardiac sarcoidosis, haemochromatosis)\n* End-stage renal disease (eGFR \\<15 ml\u002Fmin or dialysis treatment, previous kidney transplantation)\n* Significant physical disability, mobility limitation, or dependence on another person for assistance (patient is not self-sufficient) limits participation in the study","85 Years",{"count":314,"type":23},300,"With an ageing population, the number of patients with heart failure with preserved ejection fraction (HFpEF) or diastolic heart failure is increasing rapidly. This condition is associated with significantly increased morbidity and mortality, but effective treatment options that improve prognosis are very limited.\n\nFurther understanding of the nature and determinants of this disease is needed to develop better treatments of HFpEF and to improve the prognosis and quality of life of these patients.\n\nThis study will collect a comprehensive, prospective dataset of patients with HFpEF and determine which factors influence the prognosis of this patient group.\n\nThe specific aim is to create an accurate description of the spectrum and subtypes of HFpEF enabling better tools to plan and implement individualised treatment for patients.\n\nThe main objectives of the study are:\n\n* to describe and categorize the phenotype of HFpEF patients (deep phenotyping) using the latest biochemical, functional and imaging techniques\n* identifying factors affecting prognosis and potential new prognostic markers\n* prospective follow-up of a contemproary cohort of HFpEF patients to assess outcomes, such as hospitalisations for heart failure, mortality, and quality of life\n* identification of specific or aberrant HFpEF phenotypes for genetic studies.\n\nTarget population:\n\n* Patients (minimum18 years old) with hospitalization for heart failure (1' or 2' cause for hospitalization) or outpatients with heart failure AND\n* Left ventricular ejection fraction (LVEF) \\>40% within 12 months prior to or during index hospitalization (assessed by ECHO, MRI, LV-cineangiography or radionuclide imaging) AND\n* Elevated BNP\u002FNTproBNP AND\n* Impaired myocardial relaxation (diastolic dysfunction) assessed by tissue doppler imaging (TDI) velocities on ECHO: lateral mitral annulus velocity (lat E') \\>9cm\u002Fs or septal annulus velocity (sept E') \\>8 cm\u002Fs\n* Both de-novo HF and patients with previously diagnosed HF will be eligible\n\nThe study prospective, observational study is carried out at Helsinki and Uusimaa Hospital District (HUS).",[317],"Heart Failure with Preserved Ejection Fraction",[319,320,321,322],"HFpEF","iCPET","heart failure","invasive hemodynamics","2024-12-13",{"date":325,"type":41},"2024-12-18",{"date":327,"type":41},"2024-08-23",{"date":329,"type":23},"2030-06",{"name":47,"class":48},{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":222,"minAge":19,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":24,"phases":340,"briefSummary":341,"conditions":342,"keywords":344,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":49},"100489602","personalized-treatment-for-endometrial-carcinoma-100489602","NCT05655260","PErsonalized TReatment for Endometrial Carcinoma","PETREC","Inclusion Criteria:\n\n* Age 18 to 100 years\n* WHO performance status 0 to 2\n* Stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>100 years\n* WHO performance status \\>2\n* Uterine sarcoma\n* A history of malignancy within 5 years\n* Previous pelvic radiotherapy\n* An interval of \\>30 days between surgery and start of chemotherapy or \\>8 weeks between surgery and start of radiotherapy (longer intervals may be permitted with investigator´s approval)","100 Years",{"count":314,"type":23},[26],"The goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma. Specifically, the invesigators want to compare:\n\n* Chemotherapy vs. chemoradiotherapy in p53 abn subtype and nonendometrioid carcinomas.\n* Vaginal brachytherapy vs. whole pelvic radiotherapy in the MMR-D molecular subgroup.\n* Vaginal brachytherapy vs. whole pelvic radiotherapy in the NSMP molecular subgroup.",[343],"Endometrial Adenocarcinoma",[345,346,347],"Endometrial carcinoma","Molecular classification","Adjuvant therapy","2024-12-03",{"date":350,"type":41},"2024-12-06",{"date":352,"type":41},"2022-02-08",{"date":354,"type":23},"2028-12-31",{"name":47,"class":48},{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":24,"phases":366,"briefSummary":367,"conditions":368,"keywords":369,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":49},"100557739","interventions-for-the-wellbeing-of-students-at-the-university-of-helsinki-100557739","NCT06542029","Interventions for the Wellbeing of Students At the University of Helsinki","Groups 4 Health (Ryhmät Kuntoon) for Mental Well-being: a Feasibility and Controlled Effectiveness Study At the University of Helsinki","INSIGHT","Inclusion criteria\n\n* Adult (age 18 and above)\n* Student in the University of Helsinki, Finland\n* Able to speak\u002Fread Finnish, Swedish, or English\n\nExclusion criteria:\n\n\\- None",{"count":365,"type":23},600,[26],"The psychological, social, and health consequences of psychological ill-being, particularly loneliness, are well-documented among students, which underlines the importance of providing adequate support. Groups 4 Health (G4H) is a promising psychosocial group intervention focused on improving well-being by supporting social connectedness and belonging.\n\nIn earlier Australian studies G4H has decreased loneliness and social anxiety and increased group memberships significantly more than treatment as usual. When compared to cognitive behavioral therapy G4H has showed continued reduction in the participants' loneliness at the end of the intervention period and in the follow-up.\n\nResearch on the G4H intervention's effectiveness outside Australia and research on the intervention's cost-effectiveness is lacking. Therefore, this clinical study investigates the feasibility, effectiveness, and cost-effectiveness of the G4H among the University of Helsinki students in Finland.\n\nThe effectiveness and cost-effectiveness of the G4H will be compared to two other active intervention groups: the well-being groups facilitated by the study psychologists at the University of Helsinki and an online course for students' well-being. Effectiveness will also be compared to students who do not participate in any well-being courses or interventions. The investigators hypothesize that all the active intervention groups promote student well-being.\n\nQuestionnaires and University of Helsinki registry data will be gathered before and after the interventions to evaluate the effectiveness and cost-effectiveness of the interventions. The factors that influence the intervention's effectiveness and cost-effectiveness will also be studied.\n\nIn addition to these research questions, qualitative methods are used to explore the challenges and possibilities identified in the G4H-intervention regarding inclusion and equality.",[189],[192,193,194,190,195,196,197,198,199,370,371,372,373,200,374,375],"Equality","Inclusion","Motivation","Controlled study","Adherence","Acceptance and Commitment Therapy","2024-09-06",{"date":378,"type":41},"2024-09-19",{"date":380,"type":41},"2022-03-20",{"date":382,"type":23},"2026-07-31",{"name":47,"class":48},{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":404},"100559480","accuracy-of-eeg-slow-wave-activity-in-predicting-favourable-outcome-in-patients-with-hypoxic-brain-injury---a-substudy-of-stepcare-trial-100559480","NCT06564675","Accuracy of EEG Slow Wave Activity in Predicting Favourable Outcome in Patients With Hypoxic Brain Injury - A Substudy of STEPCARE Trial","PROPEASTEPCARE","Inclusion Criteria:\n\n* Age 18 years or older\n* OHCA, with sustained ROSC\n* Unconscious after ROSC\n* No limitations to full life support\n* Randomized to STEPCARE Trial in a participating center with Brainstatus device available\n\nExclusion Criteria:\n\n* age \\\u003C18\n* Previously randomized to STEPCARE\n* Trauma or hemorrhage as the reasons for arrest\n* Suspected or confirmed intracerebral hemorrhage\n* Allergy to adhesive material\n* Damaged skin at the frontal-temporal are preventing electrode attachment","110 Years",{"count":314,"type":23},"This is an observational substudy embedded in the STEPCARE Trial. The study involves EEG analysis, covered by the ethics approval of STEPCARE Trial. The investigators aim to compare the accuracy of a continuously measured algorithm-based EEG index, C-Trend Index, with retrospective visual analysis of continuous EEG in predicting favorable functional outcome in adult patients treated in intensive care units after out-of-hospital cardiac arrest. The primary hypothesis is that the accuracy of C-Trend Index has at least 10% better accuracy in predicting favorable outcome than the visual analysis of cEEG, when assessed early, 9-12 hours after return of spontaneous circulation (ROSC).",[395],"Out-Of-Hospital Cardiac Arrest","2024-08-26",{"date":398,"type":41},"2024-08-28",{"date":400,"type":41},"2023-08-01",{"date":402,"type":23},"2027-03-03",{"name":47,"class":48},4,{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":413,"targetDuration":4,"studyType":24,"phases":415,"briefSummary":416,"conditions":417,"keywords":422,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":4},"100527561","cost-effectiveness-impact-of-a-workplace-based-intervention-to-reduce-occupational-sitting-time-in-office-based-workers-100527561","NCT06149364","Cost-effectiveness, Impact of a Workplace-based Intervention to Reduce Occupational Sitting Time in Office-based Workers","Cost-effectiveness and Impact of a Workplace-based Intervention to Reduce Occupational Sitting Time Among Office-based Workers: a Randomized Controlled Trial","ISKE","Inclusion Criteria:\n\n* working at least six full time hours\n* Age of 18-65 years\n* Speaking Finnish language\n* Having designated access to internet\n* Telephone, and a desk within their workplace (home and away from home workplaces will be considered).\n\nExclusion Criteria:\n\n* Non-ambulatory\n* Pregnant\n* Those participating in other RCTs\n* Those planning relocation",{"count":414,"type":23},140,[26],"The purpose of this study is to examine the impact and cost effectiveness of a workplace-based intervention aimed at reducing prolonged occupational sitting among office-based workers. The study will be conducted in three phases. Phase I: is an Integrative review on economic evaluations of workplace-based interventions for reducing occupational sitting time. Phase II: is a secondary analysis of register data within the Northern Finland Birth Cohort 1966 (NFBC-1966). This is aimed at evaluating the association between prolonged sitting time with societal and\u002For organization economic perspective across different occupational categories at midlife. Phase III will be a Randomized Control Trial (RCT) of an office-based intervention designed to reduce prolonged occupational sitting time. The sample for the RCT will be 140 office-based workers - 70 participants will be enrolled in the control group whilst 70 participants will be enrolled within the intervention group. The study will be conducted from 2021 to 2025. An article-based dissertation will be completed at the end of the study, this will be mainly based on four articles that will be published in international peer reviewed journals.",[418,419,420,421],"Physical Inactivity","Sedentary Behavior","Occupational Diseases","Physical Activity",[423,424,425,426,427,428,429,430,431],"Cost-effectiveness","Economic evaluation","Randomized control trial","Sitting time","Workplace","Office workers","Productivity","Absenteeism","RCT","2024-04-08",{"date":434,"type":41},"2024-04-09",{"date":436,"type":23},"2024-06",{"date":438,"type":23},"2027-12",{"name":47,"class":48},{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":222,"minAge":4,"maxAge":4,"enrollmentInfo":447,"targetDuration":449,"studyType":95,"phases":4,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":459,"locationsCount":49},"100525103","systems-oncology-approach-to-optimize-ovarian-cancer-treatment-100525103","NCT06117384","Systems Oncology Approach to Optimize Ovarian Cancer Treatment","ONCOSYS-OVA","Inclusion Criteria:\n\n* Patients diagnosed with ovarian cancer\n* Available tumor tissue\u002Fblood samples\n\nExclusion Criteria:\n\n* Inability to consent to the study",{"count":448,"type":23},500,"5 Years","The overall aim is to identify effective therapeutic strategies to ovarian cancer (OC) using serial tumor, ascites and blood samples, and carry out state-of-the-art sequencing approaches, functional assays and associated bioinformatics to understand mechanisms behind chemoresistance in OC and identify new treatment options for OC patients. In this observational trial, we will systematically collect, analyze and interpret functional, molecular and clinical data from real-world ovarian cancer patients.",[452],"Ovarian Cancer","2023-11-01",{"date":455,"type":41},"2023-11-07",{"date":457,"type":41},"2022-01-01",{"date":133,"type":23},{"name":47,"class":48},""]